Virological Failure in HIV to Triple Therapy With Dolutegravir-Based Firstline Treatment: Rare but Possible.

Pena, M JChueca, ND'Avolio, AZarzalejos, J MGarcia, F2023-01-252023-01-252018-12-102328-8957http://hdl.handle.net/10668/13411We describe a case of virological failure during initial treatment with tenofovir disoproxil fumarate/emtricitabine/dolutegravir twice daily, with concomitant rifampin treatment of staphylococcal infection, selection of R263K + E157Q, and low plasma dolutegravir levels. Using rifampin together with dolutegravir may require closer follow-up, and, if possible, plasma dolutegravir levels should be monitored.enAttribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/dolutegravirfailurefirstlineVirological Failure in HIV to Triple Therapy With Dolutegravir-Based Firstline Treatment: Rare but Possible.research article30631792open access10.1093/ofid/ofy332PMC6324549https://academic.oup.com/ofid/article-pdf/6/1/ofy332/33575984/ofy332.pdfhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6324549/pdf